Please select an option below to help us tailor your newsletter to best suit your content interests!
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, IBC
Stage 3
Phase 3
Open to Enrollment
Peri-operative
Carboplatin, Paclitaxel, Pembrolizumab
Chemotherapy, PD-1 inhibitor
Greg Vidal, MD, PhD
SWOG
ER negative, PR negative, HER2 negative, TNBC
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC, ER+ breast cancer
Stage 3
Phase 3
Open to Enrollment
Adjuvant
Imlunestrant
SERD
Greg Vidal
Eli Lilly and Company
invasive breast carcinoma, Estrogen receptor positive (ER+), HER2 negative
Inclusion Criteria:
Exclusion Criteria:
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, ER positive breast cancer
Stage 2
Phase 3
Open to Enrollment
Adjuvant
chemotherapy, ovarian suppression, and endocrine therapy
chemotherapy, ovarian suppression, and endocrine therapy
Greg Vidal, MD, PhD
NRG Oncology
adenocarcinoma
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
VIEW TRIAL ON CLINICALTRIALS.GOVIBC, Breast Cancer
Stage 3
Phase 3
Open to Enrollment
Adjuvant
Atezolizumab, Trastuzumab emtansine
PD-L1 inhibitor, HER2 ADC
Greg Vidal, MD, PhD
Hoffman La-Roche
HER2 + IBC
Inclusion Criteria:
Exclusion Criteria:
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple negative breast cancer, TNBC
Stage 3
Phase 3
Open to Enrollment
Adjuvant
datopotamab deruxtecan (Dato-DXd)
ADC, Trop2 with Topo1 inhibitor payload
Greg Vidal, MD, PhD
AstraZeneca
Triple negative, ER negative, PR negative, HER2 negative
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, MBC, IBC
Stage 4
Phase 3
Open to Enrollment
2nd line endocrine
Giredestrant
SERD
Greg Vidal, MD, PhD
Genentech, Inc.
ER positive, HER2 negative
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, ER+ breast cancer, HER2 negative breast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
Failure of single-agent endocrine therapy
Giredestrant
SERD
Greg Vidal, MD, PhD
Hoffmann La-Roche
ER+, HER2 -
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st
Giredestrant, Phesgo, taxane
SERD, anti-HER2
Saradasri Wellikoff, MD
Roche
HER2 positive, ER positive
A Phase 1b/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 1
Open to Enrollment
2nd Line
Atezolizumab with Ipatasertib or ladiratuzumab-vidotin or Bevacizumab or Cobimetinib or Capecitabine or Combination Chemo
PD-L1 antibody with either PI3Ki or LIV1A ADC or MEKi or VEGFRi or chemo
Greg Vidal, MD, PhD
Hoffman-La Roche
ER- (negative), PR- (negative), HER2- (negative)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)
VIEW TRIAL ON CLINICALTRIALS.GOVbreast cancer
Stage 4
Phase 2
Open to Enrollment
first or second
Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib, Everolimus
multiple
Gregory Vidal, MD
Hoffmann-La Roche
ER+
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma